The PBM story you haven’t heard: Hidden fees quadrupled in two years
By Robert Zirkelbach | March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...
Read More
Health Affairs study misses the mark on medicine costs
By Holly Campbell | January 28, 2019
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the...
Read More
New government data show medicine price growth continues to decline
By Holly Campbell | January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.
Read More
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
By Holly Campbell | October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...
Read More
Americans want to know more than just the list price of a medicine—and we’re answering their call
By Robert Zirkelbach | October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...
Read More
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
By Katie Koziara | October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...
Read More
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
By Juliet Johnson | September 24, 2018
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program’s successful competitive structure. While these changes closed the donut hole a year...
Read More
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
By Juliet Johnson | September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines. These...
Read More
New study finds some hospitals mark up medicine prices at least 700 percent
By Holly Campbell | September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...
Read More
69 percent of patients abandon medicines when cost sharing is more than $250
By Holly Campbell | August 23, 2018
New research from the IQVIA Institute for Human Data Science shows that when cost sharing rises, patients are more likely to abandon their medicines. In 2017, 69 percent of commercially insured...
Read More
Medicare Monday (100)
340B Spotlight (39)
Cost & Consequence (0)
